Rintega (rindopepimut) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme (GBM) that test positive for the EGFR variant (EGFRvIII).
Peter J. Sciavolino, PhD
Advertisement
Articles by Peter J. Sciavolino, PhD
Advertisement
Latest Updated Articles
Rintega Receives Breakthrough Designation for EGFRvIII-Positive GlioblastomaPublished: February 24th 2015 | Updated:
Advertisement
Advertisement
Trending on CURE
1
FDA Grants Exousia Pro Orphan Drug Designation in Glioma
2
With Cancer, 'Your Outlook Will be Significant in Beating this Disease'
3
What to Know About the FDA Approval of Blenrep for Multiple Myeloma
4
Sharing Insights Into a Multiple Myeloma Journey
5
